CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Biohaven's BHV-1420 reduces disease-driving antibodies by over 90% in mouse study

By Public Technologies
  • Biohaven presented preclinical results for BHV-1420 in membranous nephropathy at ASN Kidney Week on Oct. 24, 2026.
  • Laboratory testing showed recognition of most patient autoantibodies; a single injection rapidly reduced circulating disease-driving antibodies in mice.
  • The investigational drug targets harmful autoantibodies for liver degradation without broad immunosuppression.
  • BHV-1420 becomes the second program in its TRAP kidney disease portfolio, built on technology exclusively licensed from Yale University.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260730PR_NEWS_USPR_____NE80438) on October 26, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk